Goldman Sachs Aktienanleihe BAYN .../ DE000GZ5VPZ2 /
15.11.2024 14:59:50 | Изменение-0.25 | Бид22:00:26 | Предложение22:00:26 | Базовый актив | Цена исполнения | Дата истечения | Тип опциона |
---|---|---|---|---|---|---|---|
34.65EUR | -0.72% | - Величина цены спроса: - |
- Величина цены предложения: - |
BAYER AG NA O.N. | 62.00 - | 27.12.2024 | Call |
GlobeNewswire
02.08
Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting A...
GlobeNewswire
11.07
AskBio receives FDA Fast Track and MHRA Innovation Passport designations for AB-1005 investigational...
GlobeNewswire
30.05
Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines
GlobeNewswire
30.05
BlueRock Therapeutics receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’...
GlobeNewswire
28.05
Pairwise and Bayer Expand CRISPR Leafy Greens Market through Licensing Agreement
GlobeNewswire
02.05
AskBio Announces Nine Presentations at American Society of Gene and Cell Therapy 27th Annual Meeting...
GlobeNewswire
18.04
AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in conge...
GlobeNewswire
16.04
AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson’...
GlobeNewswire
11.04
Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from...
GlobeNewswire
25.03
BlueRock Therapeutics and Foundation Fighting Blindness announce collaboration to expand the Uni-Rar...
GlobeNewswire
06.03
BlueRock Therapeutics phase I clinical trial for Parkinson’s disease continues to show positive tren...
GlobeNewswire
04.03
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
GlobeNewswire
15.02
2Blades Delivers on Project with Bayer Crop Science to Combat Asian Soybean Rust
- Первая страница
- Назад
- 1
- 2
- 3
- 4
- Следующий
- Последняя страница